Miller Mary 4

What Happened
Mary Miller, Chief Legal Officer of Acrivon Therapeutics (ACRV), received a derivative equity award covering 129,760 shares on March 1, 2026. The Form 4 reports the acquisition as an award/grant (code A) with a transaction price of $0.00 (reported value $0). This is a compensation grant (not a market purchase or sale) and vests over time rather than delivering immediate transferable shares.

Key Details

• Transaction date: 2026-03-01; Form 4 filed: 2026-03-03 (filed within the usual two-business-day window).
• Nature: Derivative award (listed as an option in the footnote); reported transaction price $0.00.
• Amount: 129,760 shares subject to the award.
• Vesting: 25% vests on March 1, 2027; remaining shares vest in 36 substantially equal monthly installments thereafter, subject to continuous service (per footnote).
• Shares owned after transaction: Not specified in the supplied filing details.
• Filing code: A = Award/Grant. No 10b5-1 plan, tax withholding, or late-filing flag noted in the provided info.

Context
This was a time‑based equity award as part of executive compensation. As a derivative (option-like) grant, it does not represent an immediate cash purchase or sale and will only turn into vested/owned shares over time (and may require exercise depending on award terms). Such grants are common for retention and incentive purposes and should be viewed as compensation, not a direct signal of insider buying or selling.